Book a demo

Chemical intelligence powered by cypris.ai

Ficaprenol

(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaen-1-ol · also: undecaprenol, all-trans-undecaprenol

FormulaC55H90O
Mol. weight767.324
PubChem CID5280474
InChIKeyTXKJNHBRVLCYFX-RDQGWRCRSA-N
SMILESCC(=CCC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CC/C(=C/CO)/C)/C)/C)/C)/C)/C)/C)/C)/C)/C)C
416Patents
21Research papers
44Patents - last 3 years
1Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1GlaxoSmithKline Biologicals SA55
2Eisai Co Ltd20
3Cornell University14
4Nisshin Seifun Group Inc13
5Janssen Pharmaceuticals Inc12
6Purdue Research Foundation12
7North Carolina State University11
8Toyota Motor Corp11
9University of Iowa Research Foundation UIRF11
10AstraZeneca AB10

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations230
2C07KPeptides177
3A61PTherapeutic activity (drug indications)175
4C12NMicroorganisms, enzymes165
5Y02AClimate change adaptation91
6C12PFermentation, enzyme processes87
7C12YEnzyme nomenclature (EC numbers)60
8C12QMeasuring/testing involving enzymes55
9C12R34
10G01NInvestigating / analysing materials32

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Use of undecaprenol kinase inhibitors to inhibit cell wall biosynthesis2001ユニバーシティー オブ フロリダ0
USE OF INHIBITORS OF UNDECAPRENOL KINASE TO INHIBIT CELL WALL BIOSYNTHESIS2000University of Florida0
USE OF INHIBITORS OF UNDECAPRENOL KINASE TO INHIBIT CELL WALL BIOSYNTHESIS1998University of Florida0
Use of inhibitors of undecaprenol kinase to inhibit cell wall biosynthesis1998University of Florida0

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Dominique Mengin‐LecreulxCentre National de la Recherche Scientifique2
2Frederic A. TroyUniversity of California, Davis2
3Mary OsbornUConn Health2
4Tadeusz ChojnackiPolish Academy of Sciences2
5Adrien DucretUniversité Claude Bernard Lyon 11
6Ahmed BouhssInstitut de Biochimie et Biophysique Moléculaire et Cellulaire1
7Amy E. TrunkfieldUniversity of Warwick1
8Anna MüllerUniversity of Bonn1
9Barbara C. McGrathUConn Health1
10Bruce E. Holbein1

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of Ficaprenol?

Ficaprenol has the molecular formula C55H90O with a molecular weight of 767.324. Its canonical chemical name is (2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaen-1-ol, and it is also known by the synonyms undecaprenol and all-trans-undecaprenol.

Which organizations hold the most patents related to Ficaprenol?

GlaxoSmithKline Biologicals SA holds the largest patent portfolio with 55 patents, followed by Eisai Co Ltd with 20 patents and Cornell University with 14 patents. Other significant patent holders include Nisshin Seifun Group Inc, Janssen Pharmaceuticals Inc, and Purdue Research Foundation.

What are the main research applications of Ficaprenol based on patent classification?

The largest share of patents is classified under A61K (pharmaceuticals), with 230 patents, followed by C07K (organic chemistry) with 177 patents and A61P (therapeutic uses) with 175 patents. Biotechnology applications are also prominent, with C12N receiving 165 patents and C12P (fermentation and enzyme technology) receiving 87 patents.

What research topics are associated with Ficaprenol in the scientific literature?

Published research on Ficaprenol covers Lipid Membrane Structure and Behavior, Bacterial Genetics and Biotechnology, and Genomics and Phylogenetic Studies. Notable papers include studies on lipopolysaccharide translocation, quantitative analysis of undecaprenyl phosphate pool levels in bacterial membranes, and investigation of undecaprenol kinase activity in Streptococcus mutans.

How has patent activity for Ficaprenol evolved in recent years?

Patent filing activity shows variability over time, with 21 patents filed in 2023 and 19 in 2025, compared to 10 patents in both 2019 and 2020. In the last three years, 46 patents have been filed. Scientific publication activity has been minimal, with only 1 paper published in the last three years out of a total of 21 papers in the coverage.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial